Barclays Issues Positive Forecast for CRISPR Therapeutics (NASDAQ:CRSP) Stock Price

CRISPR Therapeutics (NASDAQ:CRSP) had its price objective raised by analysts at Barclays from $55.00 to $56.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has an “equal weight” rating on the stock. Barclays‘s price objective suggests a potential upside of 41.34% from the stock’s previous close.

Other equities analysts also recently issued reports about the stock. Chardan Capital restated a “buy” rating and set a $94.00 price objective on shares of CRISPR Therapeutics in a research note on Tuesday, December 10th. StockNews.com upgraded shares of CRISPR Therapeutics to a “sell” rating in a research note on Monday, December 30th. Royal Bank of Canada restated a “sector perform” rating and set a $53.00 price objective on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. TD Cowen upgraded shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 price objective for the company in a research note on Wednesday. Finally, HC Wainwright assumed coverage on shares of CRISPR Therapeutics in a research note on Monday, February 3rd. They issued a “buy” rating and a $65.00 target price for the company. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $75.28.

CRISPR Therapeutics Stock Up 0.5 %

Shares of CRSP opened at $39.62 on Wednesday. CRISPR Therapeutics has a 12-month low of $36.52 and a 12-month high of $91.10. The firm has a market capitalization of $3.38 billion, a price-to-earnings ratio of -14.00 and a beta of 1.67. The stock’s 50-day moving average price is $42.45 and its 200 day moving average price is $46.40.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. Equities research analysts expect that CRISPR Therapeutics will post -5.08 EPS for the current year.

Insider Transactions at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 15,000 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $55.10, for a total value of $826,500.00. Following the transaction, the chief executive officer now owns 181,540 shares in the company, valued at $10,002,854. The trade was a 7.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On CRISPR Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of CRSP. Highline Wealth Partners LLC purchased a new position in CRISPR Therapeutics during the fourth quarter worth about $39,000. Western Pacific Wealth Management LP boosted its holdings in CRISPR Therapeutics by 100.0% during the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock worth $39,000 after purchasing an additional 500 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new position in CRISPR Therapeutics during the third quarter worth about $40,000. Darwin Wealth Management LLC purchased a new position in CRISPR Therapeutics during the third quarter worth about $43,000. Finally, Eastern Bank purchased a new position in CRISPR Therapeutics during the third quarter worth about $70,000. 69.20% of the stock is owned by institutional investors.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.